The present disclosure relates to a drug delivery investigation device to study biomechanical tissue response and injection device performance.
Drug delivery devices, such as wearable injection devices, infusion pumps, automatic injectors, and the like, have the benefit of providing therapy to the patient at a location remote from a clinical facility and/or while being worn discretely under the patient's clothing. A wearable medical device, for example, can be applied to the patient's skin and configured to automatically deliver a dose of a pharmaceutical composition within a predetermined time period after applying the wearable medical device to the patient's skin, such as after a 27 hour delay. After the device delivers the pharmaceutical composition to the patient, the patient may subsequently remove and dispose of the device. Similarly, a non-wearable device, such as an auto-injector, can be used to puncture a patient's skin and automatically deliver a dose of a medication from a reservoir and through a needle. Other non-wearable drug delivery devices, such as an infusion pump, can deliver a dose of medication through a catheter or port.
In certain circumstances, due to the medium in which the liquid is being injected, the flow of fluid leaving the device may be impaired, which can lead to increased pressure in the fluid path of the device. When the pressure rises above a certain threshold, the integrity of the fluid path may be compromised causing a leak within the device and a failure to deliver the full dose of medicament. A fluid leak within the device, which may correspond to a pressure drop within the fluid path of the device, may also cause damage to the device and subsequent system failures as well as potential contamination concerns due to contact between the fluid and the device.
Human subcutaneous tissue is composed of various cell types, extracellular matrix (ECM) constituents, microstructures, and macroscopic arrangement of cells and ECM. Those elements contribute to the mechanical properties of the tissue. The tissue may also include lymphatic system and blood vessels, and has intrinsic fluid absorption and retention properties. These characteristics vary among individuals, location within the body, and over the course of an injection may cause variable degrees of resistance to the infusion of fluids at the site of injection. When the resistance of the tissue is too high or the absorption rate is too low for a given delivery flow rate from the device, the pressure may build up and reach values above the threshold where the fluid line and other components may be compromised.
In one aspect or embodiment, a drug delivery investigation device includes a needle insertion mechanism having a cannula, a flow path having an inlet configured to be in fluid communication with a fluid source and an outlet, connection tubing extending between the outlet of the flow path and the needle insertion mechanism, with the connection tubing in fluid communication with the cannula and the flow path, a flow sensor positioned between the inlet and the outlet of the flow path, and a pressure sensor positioned between the inlet and the outlet of the flow path.
The pressure sensor may be positioned between the outlet of the flow path and the flow sensor. The flow sensor may be an inline flow sensor. The device may further include a base, where the needle insertion mechanism, the flow path, the flow sensor, and the pressure sensor are supported by the base. The device may further include at least one adhesive pad attached to the base, where at least a portion of the adhesive pad is configured to be moveable relative to the base. The at least one adhesive pad may include a connection member configured to be connected to the base and an adhesive member attached to the connection member at one or more discrete locations to allow a portion of the adhesive member to move relative to the connection member. The cannula may be configured to extend through the adhesive pad. The adhesive pad may be a first disc-shaped pad and a second disc-shaped pad spaced from the first disc-shaped pad.
The drug delivery investigation device may include a manifold, with the manifold defining the outlet of the flow path and receiving the pressure sensor. Extension tubing may extend between the manifold and the flow sensor, where the flow path is defined by the flow sensor, the extension tubing, and the manifold, and where the extension tubing and the connection tubing are formed from a low mechanical compliance material.
The needle insertion mechanism may include a guide and a needle holder, with the needle holder configured to be received within the guide and moveable relative to the guide. The guide may include a plurality of resilient arms defining an interior space configured to receive the needle holder, with the plurality of resilient arms each including a cam surface configured to engage an engagement surface of the needle holder. The needle holder may have a first position where the engagement surface is engaged with the cam surface and a second position where the engagement surface is within the interior space and spaced from the cam surface of the guide, with the plurality of resilient arms configured to deflect radially outward when the needle holder moves from the first position to the second position. The needle holder may be configured to move from the first position to the second position upon application of a predetermined axial force to the needle holder. The needle holder may include a first luer connector attached to the cannula, a second luer connecter connected to the first luer connector and in fluid communication with the connection tubing, and an actuator body configured to be manually engaged and defining the engagement surface.
The device may include at least one processor and at least one memory storage device, with the at least one processor configured to store data from the flow sensor and the pressure sensor to the at least one memory storage device. The at least one memory storage device may be configured to be connected to an external device.
The device may include at least one ancillary sensor, where the at least one ancillary sensor is at least one of an accelerometer, a photoplethysmography sensor, an ultrasonic scanner, a strain gage configured to capture skin deformation, a temperature sensor, and an impedance sensor.
In one aspect or embodiment, a method of using the drug delivery investigation device of any of the above aspects or embodiments includes: initiating streaming of data from the flow sensor and the pressure sensor to an external device; compiling and saving the data; processing the data and generating a display; and saving processed data. The method may further include: erasing data from at least one memory storage device of the drug delivery investigation device. The method may include synchronizing the output of at least two sensors. The method may include calculating an output from data obtained from at least two sensors.
In one aspect or embodiment, a method of using the drug delivery investigation device of any of the above aspects or embodiments includes: reading and writing data from the flow sensor and the pressure sensor to the at least one memory storage device of the drug delivery investigation device. The method may further include: reading and writing data from at least one ancillary sensor, where the at least one ancillary sensor is at least one of an accelerometer, a photoplethysmography sensor, an ultrasonic scanner, a strain gage configured to capture skin deformation, a temperature sensor, and an impedance sensor. The method may include synchronizing the output of at least two sensors. The method may include calculating an output from data obtained from at least two sensors.
In a further aspect or embodiment, a drug delivery investigation device includes a flow path having an inlet configured to be in fluid communication with a fluid source and an outlet, connection tubing in fluid communication with the flow path, a flow sensor positioned between the inlet and the outlet of the flow path, and a pressure sensor positioned between the inlet and the outlet of the flow path. The connection tubing may be configured to be connected to at least one of a needle insertion mechanism, a needle, and a catheter.
The above-mentioned and other features and advantages of this disclosure, and the manner of attaining them, will become more apparent and the disclosure itself will be better understood by reference to the following descriptions of embodiments of the disclosure taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. The exemplifications set out herein illustrate exemplary embodiments of the disclosure, and such exemplifications are not to be construed as limiting the scope of the disclosure in any manner.
Spatial or directional terms, such as “left”, “right”, “inner”, “outer”, “above”, “below”, and the like, are not to be considered as limiting as the invention can assume various alternative orientations.
All numbers used in the specification and claims are to be understood as being modified in all instances by the term “about”. By “about” is meant a range of plus or minus ten percent of the stated value. As used in the specification and the claims, the singular form of “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. The terms “first”, “second”, and the like are not intended to refer to any particular order or chronology, but instead refer to different conditions, properties, or elements. By “at least” is meant “greater than or equal to”.
As used herein, “at least one of” is synonymous with “one or more of”. For example, the phrase “at least one of A, B, and C” means any one of A, B, or C, or any combination of any two or more of A, B, or C. For example, “at least one of A, B, and C” includes one or more of A alone; or one or more of B alone; or one or more of C alone; or one or more of A and one or more of B; or one or more of A and one or more of C; or one or more of B and one or more of C; or one or more of all of A, B, and C.
Referring to
The drug delivery investigation device 10 is configured to measure injection parameters in-vivo and enable the characterization, assessment, and comparison of performances of injection devices. The injection parameters may be one or more of injection pressure (including peak pressure, pressure profile, average pressure, pressure decay, etc.), injection flowrate, depot formation, skin deformation (e.g., enable using an accelerometer, ultrasound, 3D scanning/reconstruction), skin bulging (wheal), etc. The drug delivery investigation device 10 is configured to enable the sensing of tissue response (e.g., tissue backpressure, fluidic resistance of tissue, tissue cracking pressure, etc.) during injection of fluid through the cannula 14. The drug delivery investigation device 10 allows for the measuring of the above parameters, which is useful in the development of a drug delivery device that use automatic or manual injection systems to deliver a dose of medication to a patient, such as through a subcutaneous injection. One example of such a drug delivery device is shown and described in U.S. Pat. No. 10,449,292 to Pizzochero et al.
During the development of such drug delivery devices, the injection parameters for a specific device and medication need to be identified and validated. Furthermore, the performances of different device or device iterations need to be quantified and objectively compared. The tissue response and in-vivo device performances are difficult to measure. The drug delivery investigation device 10 enables these difficult parameters to be measured in-vivo to obtain accurate and high quality data. As discussed in additional detail below, the drug delivery investigation device 10 is configured to minimize fluidic resistance and subsequent pressure drop between the pressure sensor 28 and the cannula 14, minimize dead volume, and minimize mechanical compliance of the flow path 16 and the connection tubing 24 between the inlet 18 and the cannula 14.
Referring again to
Referring to
Referring to
Referring to
Referring to
Referring to
In one aspect or embodiment, the method 100 further includes reading and writing data from at least one ancillary sensor, where the at least one ancillary sensor is at least one of an accelerometer, a photoplethysmography sensor, an ultrasonic scanner, a strain gage configured to capture skin deformation, a temperature sensor, and an impedance sensor. In one aspect or embodiment, the method 100 includes synchronizing the output of at least two sensors. In one aspect or embodiment, the method 100 includes calculating an output from data obtained from at least two sensors.
In one aspect or embodiment, the drug delivery investigation device 10 is configured to be primed to remove air from the flow path 16, the flow sensor 26, the pressure sensor 28, the connection tubing 24, and the extension tubing 44. The drug delivery investigation device 10 may include a sensor to enable the measurement of the depot formation and location, such as through the use of photoplethysmography, impedance tomography, ultrasonic scanner probes, thermal imaging, contact or contactless thermal sensors disposed to measure the temperature at a skin surface, strain gage capturing skin deformation, or any combination thereof.
In one aspect or embodiment, the fluid source 20, which is connectable to the inlet 18 of the flow path 16, may be a syringe pump, a peristaltic pump, a manually activated syringe, or other suitable arrangement.
In one aspect or embodiment, the flow path 16 of the drug delivery investigation device 10 is configured with channel dimension to constitute a maximum 80% of the fluidic resistance of the tissue. In one aspect or embodiment, the flow path 16 of the drug delivery investigation device 10 is configured with channel dimension to constitute a maximum 90% of the fluidic resistance of the tissue.
In one aspect or embodiment, the materials of the drug delivery investigation device 10 are selected to constitute maximum 80% of the mechanical compliance of the drug delivery investigation device 10.
Although the invention has been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred embodiments, it is to be understood that such detail is solely for that purpose and that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover modifications and equivalent arrangements that are within the spirit and scope of the appended claims. For example, it is to be understood that the present invention contemplates that, to the extent possible, one or more features of any embodiment can be combined with one or more features of any other embodiment.
This application claims priority to U.S. Provisional Application No. 63/274,296, filed Nov. 1, 2021, which is hereby incorporated by referenced in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US22/48530 | 11/1/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63274296 | Nov 2021 | US |